Geode Capital Management LLC Has $70.50 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Geode Capital Management LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 6,599,871 shares of the biopharmaceutical company’s stock after purchasing an additional 80,926 shares during the quarter. Geode Capital Management LLC owned approximately 2.21% of Amicus Therapeutics worth $70,499,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in FOLD. Xponance Inc. lifted its stake in shares of Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 936 shares during the last quarter. Hazlett Burt & Watson Inc. lifted its position in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares during the last quarter. Arizona State Retirement System boosted its holdings in Amicus Therapeutics by 2.6% during the second quarter. Arizona State Retirement System now owns 62,020 shares of the biopharmaceutical company’s stock valued at $615,000 after acquiring an additional 1,577 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Amicus Therapeutics by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 1,884 shares during the last quarter. Finally, OLD Second National Bank of Aurora bought a new position in shares of Amicus Therapeutics in the third quarter worth about $26,000.

Amicus Therapeutics Stock Up 0.7 %

Shares of NASDAQ:FOLD opened at $9.80 on Friday. The company has a market capitalization of $2.93 billion, a PE ratio of -28.82 and a beta of 0.60. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The company’s fifty day moving average is $10.48 and its 200-day moving average is $10.61. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57.

Analysts Set New Price Targets

A number of analysts have issued reports on FOLD shares. Cantor Fitzgerald raised their target price on Amicus Therapeutics from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Guggenheim boosted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Finally, StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $9,398,532.40. The trade was a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have sold 30,401 shares of company stock worth $339,363. Insiders own 2.20% of the company’s stock.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.